Across TCGA pan-cancer cohorts, PRPF40A Mutation is linked to patient survival in 4 of 34 cancer types, making it a survival-associated PRPF40A data layer compared with 24 for mass-spec protein and 6 for mass-spec protein.

The strongest signal is observed in lung squamous cell carcinoma (LUSC), where higher PRPF40A Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated PRPF40A expression acts as an unfavorable survival marker, although some lineages such as UCEC show a favorable association.

LUSC, SCLC, and BLCA are the cancer types where PRPF40A Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LUSC	OS	Median	II,III,IV	0.184	0.618	.009	12	view →
SCLC	OS	Median	All	0.082	0.653	.002	9	view →
BLCA	DFS	Median	III,IV	0.125	0.575	<.001	9	view →
UCEC	DFS	Median	All	0.976	0.829	.026	6	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

Exploration

Same gene, other analysis: PRPF40A tumor-vs-normal RNA expression · all PRPF40A data types